Our Products
Metopirone® (Metopiron®, Cormeto®, Metycor®, Metyrapone HRA, Metyrapone HRA Pharma),
Ketoconazole HRA™
and Lysodren® are developed by HRA Pharma Rare Diseases.
Therapies for Cushing’s syndrome and Adrenocortical Carcinoma.
HRA Pharma Rare Diseases therapies were developed to meet
the needs of
patients with rare and
ultra-rare diseases for a range of medical conditions. Regulatory status and access to our products
may vary
depending on the country.
If you would like further information on any of our products, please contact us.
Metopirone® (metyrapone)
The name of our product may vary depending on the country. It may be also called
Metopiron®, Cormeto®, Metycor®, Metyrapone HRA Pharma and Metyrapone HRA.
Click on the links below dependent on country for further information on the Summary of Product
Characteristics (SmPC):
United States residents
For other countries, please consult your local Summary of Product Characteristics
Ketoconazole HRA™ (ketoconazole)
Click on the link below for further information on the Summary of Product Characteristics (SmPC):
For other countries, please consult your local Summary of Product Characteristics
Lysodren® (mitotane)
Click on the links below dependent on country for further information on the Summary of Product Characteristics (SmPC):
United States residents
For other countries, please consult your local Summary of Product Characteristics